Skip to main content

NBTX · Nanobiotix S.A.

Track NBTX — free
$26.50 -0.82 (-2.98%) At close · Nov 20
Market Cap
$1.35B
Shares
50.95M
Volume · Nov 20 125.29K Avg daily vol (3M) 147.83K

Price & Indicators

 

Key stats

Close
$26.50
Fri 20 Nov
Open
$28.15
Fri 20 Nov
Average volume, 30 days
143K
shares a session
Short interest
170K
0.3% of shares · 1.4 days to cover
Day range
$26.12$28.60
Open $28.15 Close $26.50
52-week closing range
$19.97$55.07
Close $26.50 51.9% under the high
Short volume, last session
44%
Last earnings
Apr 1, 2026
Price history
Dec 2020 to Nov 2026

Latest documents

2026
Nov 9
Current report 6-K
November investor conference appearances announced

NANOBIOTIX announced management appearances at the Jefferies Global Healthcare Conference on Monday, November 16, 2026, and the UBS Global Biopharma Conference on Tuesday, November 17, 2026, in London.

7 source passages
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November: Jefferies Global Healthcare Conference in London Date: Monday, November 16, 2026 Location: London (UK) UBS Global Biopharma Conference Date: Tuesday, November 17, 2026 Location: London (UK) Open the document at this passage
Oct 26
Current report 6-K
Melanoma study shows 41.7% overall response rate with JNJ-1900

Nanobiotix reported final Phase 1 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant primary cutaneous melanoma. The overall response rate was 41.7% (10/24), including 4 complete responses, with median overall survival of 17.8 months.

3 source passages
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 17.8 months median Overall Survival Open the document at this passage
Oct 1
Current report 6-K
Current report

Nanobiotix S.A. appointed Arnd Christ chief financial officer and executive board member effective October 1, 2026; Bart Van Rhijn will step down as chief financial & business officer and board member after five years.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$13.42M
Trailing 12 months
Net income (TTM)
−$61.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-256.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+30.0%
Trailing year
Short interest
0.3%
Latest settlement · 1.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −10%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 19%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Weak
1-month return −10%
trailing
6-month return −28%
trailing
YTD return +15%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $29 › 200d $34 — 200d above 50d
Institutional flow Accumulating
+47% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.33% of shares out · ▼ -13.4% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
28 holders — near 3-yr high, broad support
Squeeze score 36
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −62%
past year
ATR 9.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
19% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $29 › 200d $34 — 200d above 50d
Institutional flow Accumulating
+47% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.33% of shares out · ▼ -13.4% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
28 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $20 Now $27 · 19% Range high $55
vs 200-day avg -23% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NBTX
Nanobiotix S.A.
this stock
$1.35B +14.6% — — 0.3%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
12.5%
Net QoQ
+559.6K sh
Top holder
JOHNSON & JOHNSON
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Falling
Shares short
170.1K
Days to cover
1.4d
Change
-26.4K sh
View
Short Volume
Short vol %
44%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$55.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
25.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 12, 2026
This year
34

Nanobiotix reported 50,968,893 shares outstanding as of October 31, 2026, alongside 54,726,179 theoretical voting rights and 54,704,061 exercisable voting rights.

View
Earnings & Events
Webcasts
Last webcast
Apr 1, 2026
View
Investor Relations
Latest news
Voting Rights and Shares Capital…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
NBTX -13.6% -9.7% -27.9% -15.5% +14.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -5.0% -0.5% -18.7% -6.8% +13.5%
Key facts CIK 1760854 CUSIP 63009J107 13F (30d) 27 filings 25 filers Visit website Investor relations